ASCO 2023 | Challenges surrounding the study of NOD2-mutant cancer

Megan Babette Barnet, MD, The Kinghorn Cancer Centre, Darlinghurst, Australia, discusses challenges associated with targeting the NOD2 gene, such as the larger number of tumor-centric biomarkers. There has been little focus on host factors that may contribute to response, as host immunogenomic profiles are not often studied before or during treatment. Secondly, the NOD2 gene has not been involved in cancer specific panels, which would require whole exome or whole genome sequencing which is difficult to obtain for some centers, due to price constraints. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.